InspireMD (NYSE:NSPR) Earns Buy Rating from Analysts at Maxim Group

Maxim Group initiated coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Monday, MarketBeat reports. The brokerage issued a buy rating and a $6.00 price objective on the stock.

InspireMD Trading Down 0.1%

Shares of NYSE:NSPR opened at $1.64 on Monday. The stock has a market capitalization of $69.45 million, a P/E ratio of -2.19 and a beta of 0.93. The stock’s 50-day moving average price is $1.81 and its 200-day moving average price is $2.15. InspireMD has a 12-month low of $1.51 and a 12-month high of $3.80.

Insiders Place Their Bets

In other InspireMD news, insider Shane Thomas Gleason sold 17,593 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $1.62, for a total value of $28,500.66. Following the completion of the sale, the insider owned 1,174,664 shares in the company, valued at approximately $1,902,955.68. The trade was a 1.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 61,194 shares of company stock valued at $99,188 in the last ninety days. Insiders own 34.06% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Aberdeen Group plc bought a new stake in shares of InspireMD in the 3rd quarter worth approximately $5,979,000. Rosalind Advisors Inc. lifted its stake in InspireMD by 70.6% in the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after acquiring an additional 1,616,644 shares during the period. Velan Capital Investment Management LP boosted its holdings in InspireMD by 137.1% in the third quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock valued at $5,166,000 after acquiring an additional 1,239,669 shares in the last quarter. Parkman Healthcare Partners LLC boosted its holdings in InspireMD by 97.6% in the third quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock valued at $5,882,000 after acquiring an additional 1,205,328 shares in the last quarter. Finally, Nantahala Capital Management LLC increased its position in InspireMD by 45.7% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock valued at $8,137,000 after purchasing an additional 1,058,467 shares during the period. Institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.